An announcement from Altimmune (ALT) is now available.
Altimmune, Inc. has appointed Andrew Shutterly as the new acting Chief Financial Officer after the sudden passing of former CFO Richard Eisenstadt. Shutterly, 36, has been with Altimmune since October 2020 and previously held roles at Meso Scale Diagnostics and Deloitte. His appointment carries no familial conflicts of interest, and he will receive a standard indemnification agreement similar to that of other executives.
For an in-depth examination of ALT stock, go to TipRanks’ Stock Analysis page.
